UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4105-4111

2003

Volltextzugriff (PDF)

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Journal of human hypertension, 2004-06, Vol.18 (6), p.367-373

2004

Volltextzugriff (PDF)

The multinational impact of migraine symptoms on healthcare utilisation and work loss

PharmacoEconomics, 2001, Vol.19 (2), p.197-206

2001

Volltextzugriff (PDF)

Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated with Zidovudine and Lamivudine

Clinical infectious diseases, 2004-08, Vol.39 (3), p.426-433

2004

Volltextzugriff (PDF)

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Journal of human hypertension, 2006-01, Vol.20 (1), p.51-58

2006

Volltextzugriff (PDF)

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

Journal of hypertension, 2005-07, Vol.23 (7), p.1425-1431

2005

Volltextzugriff (PDF)

Work and Productivity Loss in the Rizatriptan Multiple Attack Study

Cephalalgia, 2000-11, Vol.20 (9), p.830-834

2000

Volltextzugriff (PDF)

The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure

Cardiology, 1999-01, Vol.91 (3), p.189-194

1999

Volltextzugriff (PDF)

A regression-based method for estimating mean treatment cost in the presence of right-censoring

Biostatistics (Oxford, England), 2000-09, Vol.1 (3), p.299-313

2000

Volltextzugriff (PDF)

Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation

Diabetes care, 2003-03, Vol.26 (3), p.683-687

2003

Volltextzugriff (PDF)

Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom

Current therapeutic research, 2005-11, Vol.66 (6), p.475-485

2005

Volltextzugriff (PDF)

Addition of the Oral NK 1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4105-4111

2003

Volltextzugriff (PDF)

PCV52 LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: AN ECONOMIC EVALUATION OF THE LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN HYPERTENSION (LIFE) STUDY FOR GERMANY

Value in health, 2006-11, Vol.9 (6), p.A353-A353

2006

Volltextzugriff (PDF)

Population impact of losartan use on stroke in Canada

American journal of hypertension, 2005-05, Vol.18 (5), p.A228-A228

2005

Volltextzugriff (PDF)

Comparison of losartan and captopril on heart failure–related outcomes and symptoms from the losartan heart failure survival study (ELITE II)

The American heart journal, 2005-07, Vol.150 (1), p.123-131

2005

Volltextzugriff (PDF)

COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH: AN ECONOMIC EVALUATION OF THE LIFE TRIAL

Journal of hypertension, 2004-06, Vol.22 (Suppl. 2), p.S289-S290

2004

Volltextzugriff (PDF)

Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union

Kidney international, 2002-12, Vol.62 (S82), p.S68-S72

2002

Volltextzugriff (PDF)

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy

Kidney international, 2004-11, Vol.66 (S92), p.S115-S117

2004

Volltextzugriff (PDF)

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy

PharmacoEconomics, 2006-01, Vol.24 (6), p.549-558

2006

Volltextzugriff (PDF)

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study: The LIFE Substudy

Journal of human hypertension, 2004, Vol.18 (6), p.367-373

2004

Volltextzugriff (PDF)

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective

Canadian journal of cardiology, 2004-05, Vol.20 (6), p.613-618

2004

Volltextzugriff (PDF)

Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective

Nephrology (Carlton, Vic.), 2005-10, Vol.10 (5), p.520-524

2005

Volltextzugriff (PDF)

PST2 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH: AN ECONOMIC EVALUATION FOR THE NETHERLANDS BASED ON THE LIFE-STUDY

Value in health, 2005-11, Vol.8 (6), p.A150-A151

2005

Volltextzugriff (PDF)

PCVI5 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN: AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL

Value in health, 2004-11, Vol.7 (6), p.689-689

2004

Volltextzugriff (PDF)

The impact of losartan on the lifetime incidence of ESRD and costs in Mexico

Revista de investigacion clinica, 2005-05, Vol.57 (3), p.399-405

2005

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(61)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

The multinational impact of migraine symptoms on healthcare utilisation and work loss

Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated with Zidovudine and Lamivudine

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

Work and Productivity Loss in the Rizatriptan Multiple Attack Study

The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure

A regression-based method for estimating mean treatment cost in the presence of right-censoring

Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation

Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom

Addition of the Oral NK 1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

PCV52 LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: AN ECONOMIC EVALUATION OF THE LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN HYPERTENSION (LIFE) STUDY FOR GERMANY

Population impact of losartan use on stroke in Canada

Comparison of losartan and captopril on heart failure–related outcomes and symptoms from the losartan heart failure survival study (ELITE II)

COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH: AN ECONOMIC EVALUATION OF THE LIFE TRIAL

Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study: The LIFE Substudy

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective

Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective

PST2 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH: AN ECONOMIC EVALUATION FOR THE NETHERLANDS BASED ON THE LIFE-STUDY

PCVI5 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN: AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL

The impact of losartan on the lifetime incidence of ESRD and costs in Mexico

Suchergebnisse filtern